Pricing Log in Create free account

MARKER THERAPEUTICS, INC. (MRKR) vs TScan Therapeutics, Inc. (TCRX)

MARKER THERAPEUTICS, INC. and TScan Therapeutics, Inc. are both Biotechnology companies. MARKER THERAPEUTICS, INC. and TScan Therapeutics, Inc. are of similar size ($16.2M and $15.3M). TScan Therapeutics, Inc. grew revenue faster over the last twelve months: 2.15% against −27.8%. MARKER THERAPEUTICS, INC. has the higher net margin (0.00% vs −1,655.4%) and the higher return on invested capital (−566.8% vs −4,588.2%). Across the 17 metrics below, MARKER THERAPEUTICS, INC. leads on 10 and TScan Therapeutics, Inc. on 7.

Valuation

Metric MRKR TCRX Biotechnology median
P/E n/m n/m 8.50
P/S 4.22 4.20 9.71
P/B 1.65 0.43 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.32 0.64
EV/Sales 1.89 (5.27) 9.21
Earnings yield (39.42%) (395.65%) (33.15%)
Free cash flow yield (109.02%) (396.18%) (25.50%)

Profitability

Metric MRKR TCRX Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (1,695.15%) 0.00%
Net margin 0.00% (1,655.35%) 0.00%
Free cash flow margin 0.00% (1,665.18%) 0.00%
Return on equity (76.87%) (95.80%) (56.36%)
Return on assets (59.33%) (50.09%) (48.04%)
Return on invested capital (566.75%) (4,588.23%) 0.00%

Growth

Metric MRKR TCRX Biotechnology median
Revenue growth (TTM) (27.83%) 2.15% 6.02%
EPS growth (last fiscal year) 33.61% 12.28% 30.26%
Revenue growth, 5-year CAGR 50.02% 56.92% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MRKR TCRX Biotechnology median
Debt to equity 0.07 0.47 0.00
Current ratio 6.03 3.37 4.72
Net debt to EBITDA 1.32 0.90 0.96

Dividend

Metric MRKR TCRX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MRKR TCRX Biotechnology median
Market cap 15.34m 16.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack